AIBD 2019
Worsening Symptoms, Heart Failure in UC Patient Treated With Mesalamine
The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
Your search for tofacitinib returned 4 results
AIBD 2019
Timing of Biologic/JAK Inhibitor Treatment Initiation in IBD Patients Examined
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
AIBD 2019
Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
AIBD 2019
Impact of Tofacitinib on Extraintestinal Symptoms in UC Patients Examined
Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
